SG11201408047XA - Macrocyclic inhibitors of flaviviridae viruses - Google Patents
Macrocyclic inhibitors of flaviviridae virusesInfo
- Publication number
- SG11201408047XA SG11201408047XA SG11201408047XA SG11201408047XA SG11201408047XA SG 11201408047X A SG11201408047X A SG 11201408047XA SG 11201408047X A SG11201408047X A SG 11201408047XA SG 11201408047X A SG11201408047X A SG 11201408047XA SG 11201408047X A SG11201408047X A SG 11201408047XA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- foster city
- gilead sciences
- lakeside drive
- lllll
- Prior art date
Links
- 241000710781 Flaviviridae Species 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940126656 GS-4224 Drugs 0.000 abstract 15
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- NRUQNUIWEUZVLI-UHFFFAOYSA-O diethanolammonium nitrate Chemical compound [O-][N+]([O-])=O.OCC[NH2+]CCO NRUQNUIWEUZVLI-UHFFFAOYSA-O 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657550P | 2012-06-08 | 2012-06-08 | |
| PCT/US2013/044826 WO2013185103A1 (en) | 2012-06-08 | 2013-06-07 | Macrocyclic inhibitors of flaviviridae viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408047XA true SG11201408047XA (en) | 2015-01-29 |
Family
ID=48692655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408047XA SG11201408047XA (en) | 2012-06-08 | 2013-06-07 | Macrocyclic inhibitors of flaviviridae viruses |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9145441B2 (pm) |
| EP (1) | EP2861604B1 (pm) |
| JP (1) | JP6209601B2 (pm) |
| KR (1) | KR20150040265A (pm) |
| CN (1) | CN104703991B (pm) |
| AU (1) | AU2013270672B2 (pm) |
| BR (1) | BR112014030630A2 (pm) |
| CA (1) | CA2875692A1 (pm) |
| EA (1) | EA026235B1 (pm) |
| ES (1) | ES2624223T3 (pm) |
| HK (1) | HK1211285A1 (pm) |
| IL (1) | IL236005A0 (pm) |
| IN (1) | IN2014MN02652A (pm) |
| MX (1) | MX2014014766A (pm) |
| NZ (2) | NZ703040A (pm) |
| PL (1) | PL2861604T3 (pm) |
| PT (1) | PT2861604T (pm) |
| SG (1) | SG11201408047XA (pm) |
| SI (1) | SI2861604T1 (pm) |
| WO (1) | WO2013185103A1 (pm) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2861604B1 (en) | 2012-06-08 | 2017-03-01 | Gilead Sciences, Inc. | Macrocyclic inhibitors of flaviviridae viruses |
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| NZ724616A (en) | 2012-06-08 | 2018-06-29 | Gilead Sciences Inc | Macrocyclic inhibitors of flaviviridae viruses |
| HUE056470T2 (hu) | 2014-12-26 | 2022-02-28 | Univ Emory | Vírusellenes N4-Hidroxicitidin származékok |
| SI3097102T1 (en) | 2015-03-04 | 2018-02-28 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido(3,2-d)pyrimidine compounds |
| US20170008785A1 (en) * | 2015-07-07 | 2017-01-12 | Nch Corporation | System and Method for Treating Water with a Biological Based Biocide |
| MA42684A (fr) | 2015-08-26 | 2018-07-04 | Gilead Sciences Inc | Modulateurs deutérés du récepteur toll |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| CN118178444A (zh) | 2016-05-27 | 2024-06-14 | 吉利德科学公司 | 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| EP3526323B1 (en) | 2016-10-14 | 2023-03-29 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| BR112019015231A2 (pt) | 2017-01-25 | 2020-04-14 | Basf Se | processos para a preparação de compostos e compostos |
| TWI820984B (zh) | 2017-01-31 | 2023-11-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| US20220235013A1 (en) | 2017-03-21 | 2022-07-28 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN109384727B (zh) * | 2017-08-10 | 2023-07-28 | 中国科学院上海药物研究所 | 酞嗪酮类化合物、其制备方法、药物组合物及用途 |
| US11229638B2 (en) | 2017-08-22 | 2022-01-25 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| PH12022550371A1 (en) | 2017-12-07 | 2023-05-03 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| GEP20227359B (en) | 2017-12-13 | 2022-03-10 | Lupin Ltd | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| CA3097231A1 (en) | 2018-04-18 | 2019-10-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| CA3103987C (en) | 2018-07-06 | 2023-08-01 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| CA3104398A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CA3117199C (en) | 2018-10-24 | 2024-03-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| CR20210215A (es) | 2018-10-31 | 2021-06-17 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ３’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| WO2021091967A1 (en) * | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2022553858A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ｒａｓ阻害剤 |
| BR112022008535A2 (pt) * | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2021198981A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Antiviral compounds and uses thereof |
| WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| CN117683049A (zh) | 2020-09-15 | 2024-03-12 | 锐新医药公司 | 作为ras抑制剂以治疗癌症的吲哚衍生物 |
| CA3195519A1 (en) | 2020-09-18 | 2022-03-24 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN114634421A (zh) * | 2022-02-24 | 2022-06-17 | 济宁晟泰药业有限公司 | 一种达沙替尼中间体的制备方法 |
| CN120019059A (zh) | 2022-07-29 | 2025-05-16 | 辉瑞公司 | 新型acc抑制剂 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| AR006514A1 (es) * | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US20050159345A1 (en) | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
| CA2612344A1 (en) | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| AR054778A1 (es) | 2005-06-17 | 2007-07-18 | Novartis Ag | Uso de sangliferina en hcv |
| EP2011786A1 (en) | 2007-07-05 | 2009-01-07 | Laboratorios del Dr. Esteve S.A. | Indane-amine derivatives, their preparation and use as medicaments |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| US20100285056A1 (en) | 2008-01-09 | 2010-11-11 | Konkuk University Industrial Cooperation Corp. | Baculovirus-Based Vaccines |
| US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| HRP20130906T1 (hr) * | 2008-12-23 | 2013-10-25 | Janssen Pharmaceuticals, Inc. | Postupci i intermedijeri za pripravu makrocikliäśkog inhibitora hcv proteaze |
| WO2011063233A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| SI2523950T1 (sl) * | 2010-01-15 | 2017-06-30 | Gilead Sciences, Inc. | Inhibitorji flaviviridae virusov |
| WO2011090935A1 (en) | 2010-01-19 | 2011-07-28 | Merck Sharp & Dohme Corp. | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS |
| WO2011098808A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| GB201008123D0 (en) * | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| EP2618665A4 (en) * | 2010-09-21 | 2014-08-20 | Merck Sharp & Dohme | HCV NS3 proteinase inhibitor |
| UY33775A (es) | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos |
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| PE20142306A1 (es) | 2012-06-08 | 2015-01-16 | Glenmark Pharmaceuticals Sa | Amidas de compuestos de 2-amino-4-ariltiazol y sus sales |
| EP2861604B1 (en) | 2012-06-08 | 2017-03-01 | Gilead Sciences, Inc. | Macrocyclic inhibitors of flaviviridae viruses |
| NZ724616A (en) | 2012-06-08 | 2018-06-29 | Gilead Sciences Inc | Macrocyclic inhibitors of flaviviridae viruses |
-
2013
- 2013-06-07 EP EP13731203.9A patent/EP2861604B1/en not_active Not-in-force
- 2013-06-07 IN IN2652MUN2014 patent/IN2014MN02652A/en unknown
- 2013-06-07 WO PCT/US2013/044826 patent/WO2013185103A1/en active Application Filing
- 2013-06-07 US US13/913,259 patent/US9145441B2/en not_active Ceased
- 2013-06-07 AU AU2013270672A patent/AU2013270672B2/en not_active Ceased
- 2013-06-07 CA CA2875692A patent/CA2875692A1/en not_active Abandoned
- 2013-06-07 ES ES13731203.9T patent/ES2624223T3/es active Active
- 2013-06-07 PL PL13731203T patent/PL2861604T3/pl unknown
- 2013-06-07 HK HK15111999.1A patent/HK1211285A1/xx unknown
- 2013-06-07 SG SG11201408047XA patent/SG11201408047XA/en unknown
- 2013-06-07 CN CN201380039194.XA patent/CN104703991B/zh not_active Expired - Fee Related
- 2013-06-07 MX MX2014014766A patent/MX2014014766A/es unknown
- 2013-06-07 EA EA201492209A patent/EA026235B1/ru not_active IP Right Cessation
- 2013-06-07 SI SI201330574A patent/SI2861604T1/sl unknown
- 2013-06-07 NZ NZ703040A patent/NZ703040A/en not_active IP Right Cessation
- 2013-06-07 BR BR112014030630A patent/BR112014030630A2/pt not_active Application Discontinuation
- 2013-06-07 NZ NZ724503A patent/NZ724503A/en not_active IP Right Cessation
- 2013-06-07 JP JP2015516260A patent/JP6209601B2/ja not_active Expired - Fee Related
- 2013-06-07 KR KR1020157000171A patent/KR20150040265A/ko not_active Withdrawn
- 2013-06-07 PT PT137312039T patent/PT2861604T/pt unknown
-
2014
- 2014-11-30 IL IL236005A patent/IL236005A0/en unknown
-
2015
- 2015-08-07 US US14/821,458 patent/US9512175B2/en not_active Expired - Fee Related
-
2017
- 2017-09-25 US US15/715,080 patent/USRE47334E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SI2861604T1 (sl) | 2017-05-31 |
| BR112014030630A2 (pt) | 2017-06-27 |
| AU2013270672A1 (en) | 2015-01-22 |
| US20140030221A1 (en) | 2014-01-30 |
| US9512175B2 (en) | 2016-12-06 |
| CA2875692A1 (en) | 2013-12-12 |
| USRE47334E1 (en) | 2019-04-02 |
| PT2861604T (pt) | 2017-05-05 |
| HK1209730A1 (en) | 2016-04-08 |
| JP2015518904A (ja) | 2015-07-06 |
| CN104703991A (zh) | 2015-06-10 |
| MX2014014766A (es) | 2015-05-11 |
| EA201492209A1 (ru) | 2015-05-29 |
| US20150344521A1 (en) | 2015-12-03 |
| JP6209601B2 (ja) | 2017-10-04 |
| PL2861604T3 (pl) | 2017-08-31 |
| KR20150040265A (ko) | 2015-04-14 |
| HK1211285A1 (en) | 2016-05-20 |
| ES2624223T3 (es) | 2017-07-13 |
| EP2861604A1 (en) | 2015-04-22 |
| EA026235B1 (ru) | 2017-03-31 |
| US9145441B2 (en) | 2015-09-29 |
| IN2014MN02652A (pm) | 2015-08-21 |
| IL236005A0 (en) | 2015-02-01 |
| NZ724503A (en) | 2017-12-22 |
| CN104703991B (zh) | 2018-03-23 |
| AU2013270672B2 (en) | 2017-10-19 |
| WO2013185103A1 (en) | 2013-12-12 |
| NZ703040A (en) | 2016-11-25 |
| EP2861604B1 (en) | 2017-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408047XA (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| SG11201408045UA (en) | MACROCYCLIC INHIBITORS OF <i>FLAVIVIRIDAE</i> VIRUSES | |
| SG11201408064PA (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201408791TA (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
| SG11201408261UA (en) | Syringe | |
| SG11201408279QA (en) | Social sharing of security information in a group | |
| SG11201408539UA (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407115XA (en) | Carboxylic acid compounds | |
| SG11201408011SA (en) | Synthesis of antiviral compound | |
| SG11201900689RA (en) | Compounds and compositions and uses thereof | |
| SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201408186TA (en) | Pyridinone and pyridazinone derivatives |